Compare · CHE vs WGS
CHE vs WGS
Side-by-side comparison of Chemed Corp (CHE) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHE and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- CHE is the larger of the two at $6.87B, about 3.7x WGS ($1.86B).
- Over the past year, CHE is up 21.1% and WGS is down 56.3% - CHE leads by 77.4 points.
- CHE has been more active in the news (14 items in the past 4 weeks vs 5 for WGS).
- Both have 8 recent analyst ratings on file.
PerformanceCHE+21.09%WGS-56.33%
2025-11-10+0.00%2026-11-06
- Company
- Chemed Corp
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $6.87B
- $1.86B
- 1M return
- +5.87%
- -7.92%
- 1Y return
- +21.09%
- -56.33%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 14
- 5
- Recent ratings
- 8
- 8
CHE
Chemed Corp
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Latest CHE
- Chemed Corporation Declares Quarterly Dividend of 70 Cents
- President and CEO Mcnamara Kevin J sold $1,075,800 worth of Capital Stock (2,000 units at $537.90), decreasing direct ownership by 2% to 82,220 units (SEC Form 4)
- Executive vice president Lee Spencer S sold $494,196 worth of Capital Stock (920 units at $537.17), decreasing direct ownership by 6% to 13,931 units (SEC Form 4)
- Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
- SEC Form 10-Q filed by Chemed Corp
- Chemed upgraded by Jefferies with a new price target
- SEC Form 8-K filed by Chemed Corp
- Chemed Reports Third-Quarter 2026 Results
- SEC Form 4 filed by Chemed Corp
- SEC Form 4 filed by Chemed Corp
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)